New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
16:46 EDTIMUCImmunoCellular presents updated ICT-107 Phase II data
ImmunoCellular Therapeutics announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme, GBM, were presented at the 2014 American Society for Clinical Oncology, ASCO, annual meeting in Chicago. When overall survival. OS, and progression-free survival, PFS, were assessed in pre-specified patient subgroups, results favored treatment with ICT-107 over control in HLA-A2 patients within each of the two major MGMT subgroups. While the subgroups were small in size, and not powered to show statistical significance, the numeric advantages in favor of ICT-107 treated patients were shown to be large and clinically meaningful. HLA, human leukocyte antigens, are cell-surface antigen-presenting proteins. These molecules are on dendritic cells and present the tumor-associated antigens to T-cells to induce the immune response to the ICT-107 vaccine. HLA-A2 was one of two HLA types that were treated in the phase II trial. Of the two types, HLA-A2 is twice as common in the population as HLA-A1, and is the most common HLA type in North America and the EU.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IMUC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use